AstraZeneca EPS - Earnings per Share 2006-2019 | AZN

AstraZeneca annual and quarterly earnings per share history from 2006 to 2019. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • AstraZeneca EPS for the quarter ending September 30, 2019 was $0.23, a 35.29% increase year-over-year.
  • AstraZeneca EPS for the twelve months ending September 30, 2019 was $0.93, a 2.94% decline year-over-year.
  • AstraZeneca 2018 annual EPS was $0.85, a 28.27% decline from 2017.
  • AstraZeneca 2017 annual EPS was $1.19, a 14.13% decline from 2016.
  • AstraZeneca 2016 annual EPS was $1.38, a 23.77% increase from 2015.
AstraZeneca Annual EPS
2018 $0.85
2017 $1.19
2016 $1.38
2015 $1.12
2014 $0.49
2013 $1.02
2012 $2.47
2011 $3.63
2010 $2.79
2009 $2.60
2008 $2.10
2007 $1.87
2006 $1.93
2005 $1.46
AstraZeneca Quarterly EPS
Q3 2019 $0.23
Q2 2019 $0.05
Q1 2019 $0.24
Q4 2018 $0.41
Q3 2018 $0.17
Q2 2018 $0.14
Q1 2018 $0.14
Q4 2017 $0.51
Q3 2017 $0.27
Q2 2017 $0.19
Q1 2017 $0.21
Q4 2016 $0.73
Q3 2016 $0.40
Q2 2016 $0.00
Q1 2016 $0.26
Q4 2015 $0.32
Q3 2015 $0.30
Q2 2015 $0.28
Q1 2015 $0.22
Q4 2014 $-0.13
Q3 2014 $0.10
Q2 2014 $0.32
Q1 2014 $0.20
Q4 2013 $-0.21
Q3 2013 $0.50
Q2 2013 $0.33
Q1 2013 $0.41
Q4 2012 $0.61
Q3 2012 $0.60
Q2 2012 $0.63
Q1 2012 $0.64
Q4 2011 $0.58
Q3 2011 $1.27
Q2 2011 $0.77
Q1 2011 $1.04
Q4 2010 $0.57
Q3 2010 $0.54
Q2 2010 $0.73
Q1 2010 $0.96
Q4 2009 $0.54
Q3 2009 $0.73
Q2 2009 $0.59
Q1 2009 $0.74
Q4 2008 $0.43
Q3 2008 $0.60
Q2 2008 $0.56
Q1 2008 $0.52
Q4 2007 $0.43
Q3 2007 $0.46
Q2 2007 $0.48
Q1 2007 $0.51
Q4 2006 $0.47
Q3 2006 $0.51
Q2 2006 $0.51
Q1 2006 $0.45
Q4 2005 $0.39
Q3 2005 $0.38
Q2 2005 $0.38
Q1 2005 $0.32
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $126.465B $22.090B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $366.830B 15.89
Roche Holding AG (RHHBY) Switzerland $263.804B 0.00
Merck (MRK) United States $225.752B 17.49
Pfizer (PFE) United States $211.071B 12.55
Novartis AG (NVS) Switzerland $209.837B 17.71
Novo Nordisk (NVO) Denmark $135.852B 23.42
AbbVie (ABBV) United States $128.953B 10.10
Sanofi (SNY) France $116.718B 14.34
Eli Lilly (LLY) United States $113.939B 21.04
GlaxoSmithKline (GSK) United Kingdom $112.414B 13.62
Bristol-Myers Squibb (BMY) United States $95.965B 13.42
Bayer (BAYRY) Germany $71.769B 10.63
H Lundbeck (HLUYY) Denmark $7.657B 11.05